NCT06895928View on ClinicalTrials.gov

A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors

PHASE2RecruitingINTERVENTIONAL
Enrollment

400

Participants

Timeline

Start Date

March 28, 2025

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2028

Conditions
Advanced Solid Tumors
Interventions
DRUG

SHR-A2102

SHR-A2102 for injection.

DRUG

Bevacizumab Injection

Bevacizumab injection.

DRUG

Adebelimab Injection

Adebelimab injection.

DRUG

Ametinib Mesylate Tablets

Ametinib mesylate tablets.

DRUG

Osimertinib Mesylate Tablets

Osimertinib mesylate tablets.

Trial Locations (1)

030001

RECRUITING

Shanxi Cancer hospital, Taiyuan

All Listed Sponsors
lead

Shanghai Hengrui Pharmaceutical Co., Ltd.

INDUSTRY